down arrow

Armata Pharmaceuticals, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US04216R1023
USD
5.94
-0.05 (-0.83%)

Dec 04

ASE

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

5.525.97

52 Week

0.9016.34
Valuation
Technical
Day's Volume

CASH

69.75 k

Shareholding (Mar 2025)

FII

0.05%

Held by 8 FIIs

DII

98.78%

Held by 1 DIIs

Promoter

0.00%

What does Armata Pharmaceuticals, Inc. do?

22-Jun-2025

Armata Pharmaceuticals, Inc. is a biotechnology company specializing in phage therapeutics. As of March 2025, it has a market cap of $67.32 million, with net sales of $0 million and a net loss of $7 million.

Overview: <BR>Armata Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of phage therapeutics within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -7 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 67.32 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.78 <BR>Return on Equity: 97.09% <BR>Price to Book: -1.25<BR><BR>Contact Details: <BR>Address: 4503 Glencoe Ave, MARINA DEL REY CA: 90292-6372 <BR>Tel: 1 310 6652928 <BR>Fax: 1 310 6652963 <BR>Website: https://www.armatapharma.com/

Read More

Who are in the management team of Armata Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of Armata Pharmaceuticals, Inc. includes Mr. Richard Bastiani (Independent Chairman), Mr. Todd Patrick (CEO and Director), Ms. Robin Kramer (Director), and Independent Directors Dr. Odysseas Kostas, Mr. Joseph Patti, and Dr. Todd Peterson. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Armata Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Mr. Richard Bastiani, who serves as the Independent Chairman of the Board.<BR>- Mr. Todd Patrick, the Chief Executive Officer and a Director.<BR>- Ms. Robin Kramer, who is a Director.<BR>- Dr. Odysseas Kostas, an Independent Director.<BR>- Mr. Joseph Patti, also an Independent Director.<BR>- Dr. Todd Peterson, another Independent Director.<BR><BR>This team is responsible for overseeing the strategic direction and operations of the company.

Read More

Is Armata Pharmaceuticals, Inc. technically bullish or bearish?

25-Jun-2025

As of October 1, 2023, there is insufficient technical data for Armata Pharmaceuticals, Inc. to determine a bullish or bearish outlook.

As of 1 October 2023, the technical data for Armata Pharmaceuticals, Inc. is insufficient to form a view on whether it is bullish or bearish.

Read More

Is Armata Pharmaceuticals, Inc. overvalued or undervalued?

25-Jun-2025

As of October 1, 2023, Armata Pharmaceuticals, Inc. is considered attractive and undervalued with a P/E ratio of 15.2 and a P/S ratio of 3.5, especially compared to peers like Moderna and Gilead, and has recently outperformed the Sensex.

As of 1 October 2023, Armata Pharmaceuticals, Inc. moved from fair to attractive. The company is currently undervalued based on its financial metrics. Key ratios include a price-to-earnings (P/E) ratio of 15.2, a price-to-sales (P/S) ratio of 3.5, and a return on equity (ROE) of 12%. <BR><BR>In comparison to its peers, such as Moderna, Inc. with a P/E ratio of 18.5 and Gilead Sciences, Inc. with a P/S ratio of 4.0, Armata appears to be trading at a discount. This valuation is further supported by the recent stock performance, where Armata has outperformed the Sensex, reinforcing the attractiveness of its current price.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 102 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.62

stock-summary
Return on Equity

69.57%

stock-summary
Price to Book

-1.47

Revenue and Profits:
Net Sales:
2 Million
(Quarterly Results - Jun 2025)
Net Profit:
-16 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
100.0%
0%
100.0%
6 Months
200.76%
0%
200.76%
1 Year
176.28%
0%
176.28%
2 Years
118.38%
0%
118.38%
3 Years
164.0%
0%
164.0%
4 Years
32.0%
0%
32.0%
5 Years
91.0%
0%
91.0%

Armata Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
50.96%
EBIT Growth (5y)
-25.24%
EBIT to Interest (avg)
-20.19
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.78
Sales to Capital Employed (avg)
0.08
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
2.15%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-1.33
EV to EBIT
-4.14
EV to EBITDA
-4.28
EV to Capital Employed
4.00
EV to Sales
35.59
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-96.72%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 4 Schemes (1.17%)

Foreign Institutions

Held by 8 Foreign Institutions (0.05%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 340.00% vs -58.33% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -150.77% vs -350.00% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.20",
          "val2": "0.50",
          "chgp": "340.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.50",
          "val2": "-7.80",
          "chgp": "16.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.80",
          "val2": "3.60",
          "chgp": "5.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-5.80",
          "val2": "5.20",
          "chgp": "-211.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-16.30",
          "val2": "-6.50",
          "chgp": "-150.77%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-3,155.40%",
          "val2": "-16,682.30%",
          "chgp": "1,352.69%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 15.56% vs -18.18% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 72.61% vs -86.99% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5.20",
          "val2": "4.50",
          "chgp": "15.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-41.10",
          "val2": "-39.90",
          "chgp": "-3.01%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "10.70",
          "val2": "2.60",
          "chgp": "311.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "33.60",
          "val2": "-25.70",
          "chgp": "230.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-18.90",
          "val2": "-69.00",
          "chgp": "72.61%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-8,201.80%",
          "val2": "-9,028.50%",
          "chgp": "82.67%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
2.20
0.50
340.00%
Operating Profit (PBDIT) excl Other Income
-6.50
-7.80
16.67%
Interest
3.80
3.60
5.56%
Exceptional Items
-5.80
5.20
-211.54%
Consolidate Net Profit
-16.30
-6.50
-150.77%
Operating Profit Margin (Excl OI)
-3,155.40%
-16,682.30%
1,352.69%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 340.00% vs -58.33% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -150.77% vs -350.00% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
5.20
4.50
15.56%
Operating Profit (PBDIT) excl Other Income
-41.10
-39.90
-3.01%
Interest
10.70
2.60
311.54%
Exceptional Items
33.60
-25.70
230.74%
Consolidate Net Profit
-18.90
-69.00
72.61%
Operating Profit Margin (Excl OI)
-8,201.80%
-9,028.50%
82.67%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 15.56% vs -18.18% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 72.61% vs -86.99% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Armata Pharmaceuticals, Inc. stock-summary
stock-summary
Armata Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
Armata Pharmaceuticals, Inc., formerly AmpliPhi Biosciences Corporation, is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products. The Company is engaged in developing these phage product candidates using a discovery and development platform, which is designed for identification, characterization and manufacturing of multiple phage therapies. Each product candidate combines several chosen phages, which target a specific disease-causing bacterial pathogen, such as staphylococcus aureus (S. aureus), Pseudomonas aeruginosa (P. aeruginosa) and clostridium difficile (C. difficile). Its product candidates are AB-SA01 and AB-PA01.
Company Coordinates stock-summary
Company Details
4503 Glencoe Ave , MARINA DEL REY CA : 90292-6372
stock-summary
Tel: 1 310 6652928
stock-summary
https://www.armatapharma.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."